RCM
INZY

RA Capital Management’s Inozyme Pharma INZY Stock Holding History

RA Capital Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,003,653
Closed -$34.1M – 100
2021
Q2 		$34.1M Hold
2,003,653
– – 0.55% 52
2021
Q1 		$39.7M Hold
2,003,653
– – 0.6% 46
2020
Q4 		$41.4M Hold
2,003,653
– – 0.58% 45
2020
Q3 		$52.7M Buy
+2,003,653
New +$49.8M 0.96% 31

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RA Capital Management's INZY Position: Q3 2021 in Review

RA Capital Management sold out of Inozyme Pharma (INZY) in Q3 2021, closing a stake of 2,003,653 shares — an estimated $34.1M sold.

RA Capital Management first reported a position in INZY in Q3 2020 and held it in 4 quarters. The position peaked at $52.7M in Q3 2020. 52 funds tracked by Wall St. Rank hold INZY as of Q3 2021.

  • RA Capital Management reported no remaining Inozyme Pharma position as of Q3 2021 after selling out during the quarter.
  • RA Capital Management sold 2,003,653 Inozyme Pharma shares in Q3 2021, an estimated $34.1M.
  • RA Capital Management first reported a position in Inozyme Pharma in Q3 2020 and held it in 4 quarters.
  • RA Capital Management's Inozyme Pharma position peaked at $52.7M in Q3 2020.
  • 52 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2021.

Based on RA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.